ODTX
NASDAQOdyssey Therapeutics Inc.
Odyssey Therapeutics Inc. (ODTX) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 5 wire items for ODTX, including 2 SEC filings, 1 earnings update and 1 13D/G filing. The most recent was published Nov 6, 2026.
ODTX rankings
News · 26 weeks5+100%
2026-05-102026-11-01
Mix590d
- SEC Filings2(40%)
- Earnings1(20%)
- 13D/G1(20%)
- Analyst1(20%)
Activity · 52 weeks53 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
5 items- ANALYSTH.C. Wainwright resumed coverage on Odyssey Therapeutics with a new price targetH.C. Wainwright resumed coverage of Odyssey Therapeutics with a rating of Buy and set a new price target of $40.00
- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Odyssey Therapeutics Inc.SCHEDULE 13G/A - Odyssey Therapeutics, Inc. (0001882782) (Subject)
- SECSEC Form 10-Q filed by Odyssey Therapeutics Inc.10-Q - Odyssey Therapeutics, Inc. (0001882782) (Filer)
- SECOdyssey Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Odyssey Therapeutics, Inc. (0001882782) (Filer)
- PROdyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateAdditional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis Completed IND-enabling studies for OD-002, a first-in-class oral SLC15A4 inhibitor $387 million in cash, cash equivalents and marketable securities as of September 30, 2026, expected to fund operations into the second half of 2028 BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (NASDAQ:ODTX) ("Odyssey" or the "Company"), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, t
ODTX FAQ
8 questionsWhat does Odyssey Therapeutics Inc. do?
Odyssey Therapeutics is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology. Since its founding in 2021, Odyssey has built a portfolio of internally discovered and developed medicines with its first program advancing through multiple clinical milestones. Odyssey's portfolio leverages the scientific expertise of its team of experienced drug hunters and a comprehensive suite of tools to efficiently advance product...What is the latest news on ODTX?
In the last 30 days Quantisnow tracked 5 wire items for ODTX: 2 SEC filings, 1 earnings update, 1 13D/G filing and 1 analyst rating. The most recent was published on November 6, 2026.Where does ODTX stock trade?
Odyssey Therapeutics Inc. (ODTX) is listed on NASDAQ.What sector and industry is ODTX in?
Odyssey Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Odyssey Therapeutics Inc. go public?
Odyssey Therapeutics Inc. (ODTX) completed its IPO in 2026.What are analysts saying about ODTX?
Odyssey Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Buy with a $40.00 price target on 2026-11-06. Recent price targets cluster around $40.00.What companies are similar to ODTX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare ODTX side-by-side with any of them on Quantisnow.How can I track ODTX on Quantisnow?
Quantisnow aggregates Odyssey Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ODTX to receive live email and push alerts on every new disclosure.